Case report

Colchicine overdose: A South African experience, a case report

Jenna Essameb,⁎, Saul Grossbergb, Adam Mahomeda,c

a Division of Gastroenterology, Department of Internal Medicine, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa
b Charlotte Maxeke Johannesburg Academic Hospital, South Africa.
c Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

ARTICLE INFO

Keywords:
Overdose
Colchicine
Multi-organ failure

ABSTRACT

Introduction: Colchicine overdose is uncommon but is associated with a high mortality rate. It has a narrow therapeutic index and has been described to have a 100% mortality with ingestion of > 0.8 mg/kg [1,2,4,7]. The clinical presentation and management should be familiar to all those who work in acute care in order to be able to identify and treat it timeously thus preventing morbidity and mortality. Treatment is largely supportive. This is the first case of Colchicine overdose described in Sub-Saharan Africa. Written informed consent was obtained from the patient for the publication of this case report.

Case report:

A 19-year-old male, with no known comorbidities, presented to a tertiary academic hospital with multi-organ dysfunction (MOD) after ingesting 24 Colchicine tablets and 50 tablets of Procydin (a herbal antioxidant) in a suicide attempt. This is a total of 24 mg taken which equates to 0.4 mg/kg of Colchicine ingested on the day of presentation. There was no other significant history.

The patient presented with a blood pressure of 119/60 mmHg and a heart rate of 106 bpm. He had a reduced Glasgow Coma Scale score of 14/15. The rest of the examination was unremarkable.

Blood investigations included a biochemical workup. Urine dipstick and microscopy, cell-count and culture were done due to the risk of bone marrow suppression from Colchicine toxicity. An electrocardiogram (ECG), Chest X-Ray and an echocardiogram were also performed. Biochemical investigations revealed acute renal and liver dysfunction with thrombocytopenia, lymphopenia and elevated cardiac markers on admission. During his admission, he developed a pancytopenia. Improvement of these abnormalities can be seen during his admission. Significant results are show in Table 1.

The patient was managed as part of a multidisciplinary team. No acute emergency toxicological management was performed, such as activated charcoal. The patient was admitted to the medical gastro-intestinal ward and management was largely supportive. Intravenous fluids were given with strict input and output monitoring to manage his acute kidney injury. The patient developed epistaxis secondary to thrombocytopenia which was treated with Tranexamic Acid. N-acetylcysteine was given. Ertapenem was given as part of the febrile neutropenic protocol and multiple platelet transfusions were given.

Serial investigations were performed, including U + E, LFT and FBC, to monitor the patient’s response to the treatment provided.

The patient’s MOD was improving and trending towards normal by day 7. He was discharged home.

Discussion

Colchicine overdose is very uncommon but is associated with a high
Colchicine is taken orally and is rapidly absorbed, undergoing first pass metabolism [1] in the liver and wide distribution to bind to intracellular elements [1]. It undergoes “significant enterohepatic recirculation” [1] and 10–20% is renally excreted [3,5]. Toxicity occurs when colchicine binds to tubulin and disrupts the microtubular network. This leads to a decrease in protein assembly and toxicodynamics occurs is unclear and tends to be patient dependent [2]. However, some studies have defined the following as a guideline: 100% survival with a dose of < 0.5 mg/kg, 10% mortality with doses between 0.5 and 0.8 mg/kg and 100% mortality with ingestion of doses > 0.8 mg/kg [1,2,4,7].

Colchicine has multiple indications the most common being used for transient alopecia [1]. Fab fragment antibodies are the only treatment that specifically targets Colchicine toxicity; however, it is not produced commercially.

The main causes of death include MOD and sepsis [1]. Other noted causes of death are sudden arrhythmias [4,9], acute cardiac failure, cardiogenic shock, haemodynamic collapse and haematopoietic complications such as myelosuppression [4,7].

Management of Colchicine overdose predominantly involves monitoring and supportive therapy. Management can be divided into six stages [1,2]: prompt recognition of Colchicine overdose, determination of dose ingested in mg/kg, admission for observation in a high care area, early gastric decontamination, aggressive case dependent supportive management and specific treatment if available.

Early gastric decontamination includes multidose activated charcoal due to the high enterohepatic re-circulation [3]. Gastric lavage can be performed if a high dose is ingested, preferably within < 60 min of the ingestion [3].

Aggressive supportive management includes monitoring and symptomatic management. Continuous vitals and ECG monitoring should be done. Serial investigations including bloods, Chest X-Ray, echocardiogram and urine analysis should be undertaken. Symptomatic management includes anti-emetics, intravenous fluids, correction of electrolyte and acid-base disturbances and broad-spectrum antibiotics. Blood products, vasopressors, antiarrhythmics, intubation and febrile neutropaenic protocol can be given on a case to case basis. Blood products, vasopressors, antiarrhythmics, intubation and febrile neutropaenic protocol can be given on a case to case basis. Blood products, vasopressors, antiarrhythmics, intubation and febrile neutropaenic protocol can be given on a case to case basis.

| Table 1 Relevant Patient Results |
|---------------------------------|
| **Day 1** | **Day 2** | **Day 3** | **Day 4** | **Day 5** | **Day 6** | **Day 7** | **Reference** |
|-----------------|-----------|-----------|-----------|-----------|-----------|-----------|--------------|
| WCC | 8.64 | 3.77 | 1.84 | 2.08 | 3.28 | 6.60 | 11.73 | 3.9-12.6 × 10^9/L |
| Hb | 13.9 | 14.1 | 12.5 | 12.8 | 12.6 | 12.7 | 13.1 | 14-18 g/dL |
| Platelets | 96 | 53 | 33 | 19 | 18 | 38 | 76 | 186-454 × 10^9/L |
| RPI | 0.2 | | | | | | | 1-2 |
| Neutro | 1.36 | | | | | | | 1.60-6.98 × 10^9/L |
| Lympho | 0.20 | | | | | | | 1.40-4.20 × 10^9/L |
| Mono | 1.18 | | | | | | | 0.30-0.80 × 10^9/L |
| Eosino | 0.04 | | | | | | | 0.00-0.95 × 10^9/L |
| Baso | 0.06 | | | | | | | 0.00-0.10 × 10^9/L |
| CRP | 160 | | 142 | | | | | < 10 mg/L |
| INR | 1.39 | 1.39 | 1.07 | 1.1 | 1.14 | | | < 1.1 |
| Na | 132 | 136 | 135 | 136 | 136 | 136 | | 135-147 mmol/L |
| K | 4.6 | 3.9 | 3.6 | 3.6 | 4.0 | 3.7 | | 3.3-3.3 mmol/L |
| Cl | 93 | 95 | 95 | 96 | 94 | | | 99-113 mmol/L |
| Urea | 24.4 | 8.6 | 6.7 | 7.1 | 7.2 | 7.9 | | 2.6-7.0 mmol/L |
| Creatinine | 210 | 87 | 71 | 64 | 61 | 63 | | 47-90 µmol/L |
| TP | 60 | 56 | 52 | | | | | 60-85 g/L |
| Albumin | 35 | | 33 | 30 | 33 | | | 35-52 g/L |
| Tbili | 6 | 17 | 14 | 11 | | | | 0-21 µmol/L |
| DBili | 2 | 7 | 7 | 7 | | | | 0-6 µmol/L |
| ALT | 1482 | 1354 | 1078 | 626 | | | | 5-40 U/L |
| AST | 2044 | 1289 | 683 | 231 | | | | 5-40 U/L |
| ALP | 388 | 107 | 104 | 123 | | | | 40-120 U/L |
| GGT | 50 | 239 | 240 | 262 | | | | 60-120 U/L |
| Trop T | 2090 | 1655 | 1868 | | | | | < 14 ng/L |
| CKMB | 222.2 | 21.41 | 11.97 | | | | | 0-6.22 µg/L |
| Ca | > 20,000 | | | | | | | 20-200 U/L |
| Mg | 1.85 | 2.10 | | | | | | 2.15-2.50 mmol/L |
| PO4 | 0.73 | 0.72 | | | | | | 0.63-1.05 mmol/L |
| Albumin | 0.6 | 0.82 | | | | | | 0.78-1.42 mmol/L |

mortality rate [1,2]. It has a narrow therapeutic index with 80% of patients experiencing gastrointestinal side effects with therapeutic doses [1–3]. The distinction between non-toxic, toxic and lethal outcomes is unclear and tends to be patient dependent [2]. However, some studies have defined the following as a guideline: 100% survival with a dose of < 0.5 mg/kg, 10% mortality with doses between 0.5 and 0.8 mg/kg and 100% mortality with ingestion of doses > 0.8 mg/kg [1,2,4,7].

The main causes of death include MOD and sepsis [1]. Other noted causes of death are sudden arrhythmias [4,9], acute cardiac failure, cardiogenic shock, haemodynamic collapse and haematopoietic complications such as myelosuppression [4,7].

Management of Colchicine overdose predominantly involves monitoring and supportive therapy. Management can be divided into six stages [1,2]: prompt recognition of Colchicine overdose, determination of dose ingested in mg/kg, admission for observation in a high care area, early gastric decontamination, aggressive case dependent supportive management and specific treatment if available.

Early gastric decontamination includes multidose activated charcoal due to the high enterohepatic re-circulation [3]. Gastric lavage can be performed if a high dose is ingested, preferably within < 60 min of the ingestion [3].

Aggressive supportive management includes monitoring and symptomatic management. Continuous vitals and ECG monitoring should be done. Serial investigations including bloods, Chest X-Ray, echocardiogram and urine analysis should be undertaken. Symptomatic management includes anti-emetics, intravenous fluids, correction of electrolyte and acid-base disturbances and broad-spectrum antibiotics. Blood products, vasopressors, antiarrhythmics, intubation and febrile neutropaenic protocol can be given on a case to case basis. N-acetylcysteine can be considered. It was used in another case study which proposed that the antioxidant properties decreased oxidant-induced cell damage and apoptosis [1]. Dialysis can be considered for organ support, but clearance of Colchicine is not possible due to its high volume of distribution.

Specific treatment includes Granulocyte-Colony-Stimulating Factor (GCS-F) and Fragment-Antigen-Binding (Fab) antibodies. GCS-F assists regeneration of suppressed bone-marrow [6] by accelerating production of neutrophils within the bone marrow and preventing sepsis [1]. Fab fragment antibodies are the only treatment that specifically targets Colchicine toxicity; however, it is not produced commercially.
Fab antibodies consist of “the light chain and variable region of the heavy chain of antibodies derived from goats immunized with a conjugate of Colchicine and serum albumin” [1]. Fab antibodies work by binding to Colchicine, thus decreasing the levels of toxicologically active fractions, and removing the drug from peripheral sites. There are no recorded side effects to Fab antibodies thus far. The limitations to the use of this treatment are limited availability, no known correct dosage and the high costs involved in preclinical trials [8]. Fab antibodies have only been used in a few cases of Colchicine overdose and further research is needed. There is very limited data on this as an effective and realistic treatment method.

With regards to this case, the management was in keeping with that described in the literature. It was not noted whether early gastric decontamination was performed. The effect of Procysin is not known. GCS-F or Fab antibodies were not given as they are not available at the institution. The dose ingested was 0.4 mg/kg and the good outcome is consistent with the toxic dose ingestion guideline mentioned above.

Conclusion

Colchicine overdose is uncommon but carries a high mortality rate. This appears to be the first case described in Sub Saharan Africa. It is important to be able to identify and promptly treat the condition to minimize mortality. Treatment is largely supportive. Specific agents are available but require further research.

Authors’ contribution

Authors contributed as follow to the conception or design of the work; the acquisition, analysis, or interpretation of data for the work; and drafting the work or revising it critically for important intellectual content: JE contributed 70%, SG contributed 20%, and AM contributed 10%. All authors approved the version to be published and agreed to be accountable for all aspects of the work.

Declaration of competing interest

Authors declared no conflict of interest.

References

1. Finkelstein Y, Aks SE, Hutson JR, Juurlink ND, Nguyen P, Dubnov-rav C, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol [Internet] 2010;48:407–14. [cited 2019 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20566571https://doi.org/10.3109/15563650.2010.495348.
2. Herran-Monge R, Muriel-Bombin A, Garcia-Garcia M, Duenas-Laita A, Fernandez-Rodriguez MI, Prieto Lamo AM. Accidental lethal overdose of Colchicine. Med Intensiva [Internet] 2013;37(6):434–6. [cited 2019 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23122988https://doi.org/10.1016/j.medint.2012.09.002.
3. Maxwell MJ, Muthu P, Pritty PE. Accidental Colchicine overdose. A case report and literature review. Emerg Med J [Internet] 2002;19:265–7. [cited 2019 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971849/https://doi.org/10.1136/emj.19.4.265.
4. Aghabiklooei A, Zamani N, Hassanian-Moghadam H, Nasouhi S, Mashayekhian M. Acute Colchicine overdose: report of three cases. Reumatismo [Internet] 2014;65(6):307–11. [cited 2019 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24705036https://doi.org/10.4081/reumatismo.2013.720.
5. Wen-Hung H, Ching-Wei H, Chun-Chen Y. Colchicine overdose-induced acute renal failure and electrolyte imbalance. Ren Fail [Internet] 2007;29:367–70. [cited 2019 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17497548https://doi.org/10.1080/08860200601166644.
6. Blackham RE, Little M, Baker S, Augustson BM, Macquillan GC. Unsuspected Colchicine overdose in a female patient presenting as an acute abdomen. Anaesth Intensive Care [Internet] 2007;35(3):437–9. [cited 2019 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17591144.
7. Erden A, Karamar H, Huseyin Gumuscu H, Karahan S, Basak M, Aykas F, et al. Colchicine intoxication: a report of two suicide cases. Ther Clin Risk Manag [Internet] 2013;9:505–9. [cited 2019 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862685/https://doi.org/10.2147/TCRM.S54558.
8. Jouffroy R, Lambaut L, Petre Soldan M, Vivien B, Philippe P, An K, et al. A new approach for early onset cardiogenic shock in acute Colchicine overdose: place of early extracorporeal life support (ECLS)? Intensive Care Med [Internet] 2013;39(6):1163. [cited 2019 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/23612758https://doi.org/10.1007/s00134-013-2911-2.
9. Baud F, Sabouraud A, Vicaut E, Taboulet P, Lang J, Bismuth C, et al. Treatment of severe Colchicine overdose with colchicine-specific Fab fragments. NEJM [Internet] 1995;332(10):642–5. [cited 2019 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/7845428https://doi.org/10.1056/NEJM199503093321004.